Ratings by BofA Securities (Jason Gerberry)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/17/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2024 | Galapagos NV | GLPG | Downgrade | Underperform (Neutral) |
32.95 (28.42) |
-13.75% | Details | |
| 2/28/2024 | Tarsus Pharmaceuticals | TARS | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2024 | Amphastar Pharmaceuticals | AMPH | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2024 | Fractyl Health Inc | GUTS | New Coverage | Buy (N/A) |
7.60 (6.16) |
-18.95% | Details | |
| 2/8/2024 | bluebird bio | BLUE | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2024 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 1/12/2024 | Axsome Therapeutics | AXSM | Maintain | Neutral (N/A) |
|
Details | ||
| 1/12/2024 | Teva Pharma | TEVA | Maintain | Buy (N/A) |
|
Details | ||
| 1/10/2024 | Arrowhead Pharma | ARWR | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2024 | ProKidney Corp. | PROK | Downgrade | Neutral (Buy) |
1.78 (2.54) |
42.7% | Details | |
| 1/2/2024 | Ionis Pharmaceuticals | IONS | Upgrade | Buy (Neutral) |
50.59 (42.04) |
-16.9% | Details | |
| 1/2/2024 | Harmony Biosciences Holdings Inc. | HRMY | Downgrade | Underperform (Neutral) |
32.30 (28.81) |
-10.8% | Details | |
| 12/11/2023 | bluebird bio | BLUE | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2023 | Arrowhead Pharma | ARWR | New Coverage | Buy (N/A) |
23.17 (21.76) |
-6.09% | Details | |
| 11/17/2023 | Amphastar Pharmaceuticals | AMPH | New Coverage | Neutral (N/A) |
56.17 (40.84) |
-27.29% | Details | |
| 11/15/2023 | ProKidney Corp. | PROK | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2023 | Galapagos NV | GLPG | Maintain | Neutral (N/A) |
|
Details | ||
| 11/3/2023 | Karuna Therapeutics Inc. | KRTX | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2023 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 10/23/2023 | Ionis Pharmaceuticals | IONS | Upgrade | Neutral (Underperform) |
46.16 (42.04) |
-8.93% | Details | |
| 10/23/2023 | Viatris | VTRS | Downgrade | Underperform (Neutral) |
9.30 (11.38) |
22.37% | Details | |
| 10/16/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Neutral (N/A) |
|
Details | ||
| 9/13/2023 | Lyra Therapeutics | LYRA | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2023 | Teva Pharma | TEVA | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2023 | Karuna Therapeutics Inc. | KRTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/5/2023 | Axsome Therapeutics | AXSM | Maintain | Neutral (N/A) |
|
Details | ||
| 8/29/2023 | Oculis Holding AG | OCS | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Oculis Holding AG | OCS | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Cara Therapeutics | CARA | Maintain | Underperform (N/A) |
|
Details | ||
| 8/9/2023 | bluebird bio | BLUE | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Lyra Therapeutics | LYRA | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2023 | FibroGen | FGEN | Downgrade | Underperform (Neutral) |
1.77 (0.96) |
-45.76% | Details | |
| 8/8/2023 | Axsome Therapeutics | AXSM | Upgrade | Buy (Underperform) |
71.09 (71.21) |
0.17% | Details | |
| 8/3/2023 | Coherus Biosciences | CHRS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/3/2023 | Teva Pharma | TEVA | Maintain | Buy (N/A) |
|
Details | ||
| 7/19/2023 | bluebird bio | BLUE | Upgrade | Buy (Neutral) |
3.15 (0.90) |
-71.43% | Details | |
| 6/26/2023 | FibroGen | FGEN | Downgrade | Neutral (Buy) |
16.05 (0.96) |
-94.02% | Details | |
| 6/14/2023 | Oculis Holding AG | OCS | New Coverage | Buy (N/A) |
11.50 (11.98) |
4.17% | Details | |
| 5/16/2023 | Cara Therapeutics | CARA | Maintain | Underperform (N/A) |
|
Details | ||
| 5/10/2023 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Bausch Health Companies | BHC | Maintain | Underperform (N/A) |
|
Details | ||
| 5/5/2023 | Relay Therapeutics | RLAY | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Karuna Therapeutics Inc. | KRTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Organon & Co. | OGN | Maintain | Underperform (N/A) |
|
Details | ||
| 5/1/2023 | Immunovant | IMVT | New Coverage | Buy (N/A) |
16.14 (27.77) |
72.06% | Details | |
| 4/20/2023 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Neutral (N/A) |
32.97 (28.81) |
-12.62% | Details | |
| 4/18/2023 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 3/8/2023 | Cara Therapeutics | CARA | Downgrade | Underperform (Neutral) |
10.02 (0.66) |
-93.41% | Details | |
| 3/7/2023 | Coherus Biosciences | CHRS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2023 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2023 | FibroGen | FGEN | Maintain | Buy (N/A) |
|
Details | ||
| 1/9/2023 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2023 | Organon & Co. | OGN | Maintain | Underperform (N/A) |
|
Details | ||
| 1/5/2023 | Federated National Holding | FNHC | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2023 | BeyondSpring Inc. | BYSI | Maintain | Underperform (N/A) |
|
Details | ||
| 1/5/2023 | FibroGen | FGEN | Upgrade | Buy (Neutral) |
16.10 (0.96) |
-94.04% | Details | |
| 1/3/2023 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2022 | Arcellx Inc. | ACLX | New Coverage | Buy (N/A) |
28.52 (50.03) |
75.42% | Details | |
| 12/13/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/9/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/9/2022 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 12/8/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/28/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/15/2022 | Arcellx Inc. | ACLX | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2022 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/14/2022 | Teva Pharma | TEVA | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2022 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/14/2022 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2022 | Axsome Therapeutics | AXSM | Maintain | Underperform (N/A) |
|
Details | ||
| 10/14/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/14/2022 | Alkermes | ALKS | Upgrade | Neutral (Underperform) |
22.72 (23.91) |
5.24% | Details | |
| 10/14/2022 | Organon & Co. | OGN | Downgrade | Underperform (Neutral) |
24.03 (18.60) |
-22.6% | Details | |
| 10/12/2022 | DICE Therapeutics | DICE | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2022 | ProKidney Corp. | PROK | New Coverage | Buy (N/A) |
8.87 (2.54) |
-71.36% | Details | |
| 9/20/2022 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 9/13/2022 | Mirati Therapeutics | MRTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/29/2022 | Xenon Pharmaceuticals | XENE | New Coverage | Buy (N/A) |
36.97 (39.53) |
6.92% | Details | |
| 8/18/2022 | Karuna Therapeutics Inc. | KRTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/18/2022 | Relay Therapeutics | RLAY | New Coverage | Buy (N/A) |
19.34 (5.87) |
-69.65% | Details | |
| 8/8/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2022 | Teva Pharma | TEVA | Upgrade | Buy (Neutral) |
10.12 (12.95) |
27.96% | Details | |
| 8/5/2022 | Organon & Co. | OGN | Downgrade | Neutral (Buy) |
32.41 (24.03) |
-25.86% | Details | |
| 7/11/2022 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 7/11/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 7/11/2022 | Ionis Pharmaceuticals | IONS | Maintain | Underperform (N/A) |
|
Details | ||
| 7/11/2022 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 7/11/2022 | Coherus Biosciences | CHRS | Maintain | Neutral (N/A) |
|
Details | ||
| 7/11/2022 | Bausch Health Companies | BHC | Maintain | Underperform (N/A) |
|
Details | ||
| 6/29/2022 | Axsome Therapeutics | AXSM | Maintain | Underperform (N/A) |
|
Details | ||
| 6/29/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 6/7/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 6/2/2022 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 6/1/2022 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | Finch Therapeutics Group Inc. | FNCH | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | Teva Pharma | TEVA | Upgrade | Neutral (Underperform) |
7.91 (12.95) |
63.72% | Details | |
| 3/28/2022 | Karuna Therapeutics Inc. | KRTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/8/2022 | bluebird bio | BLUE | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2022 | Arcellx Inc. | ACLX | New Coverage | Buy (N/A) |
19.14 (50.03) |
161.39% | Details | |
| 3/1/2022 | Viatris | VTRS | Downgrade | Neutral (Buy) |
11.01 (11.38) |
3.36% | Details | |
| 2/1/2022 | Ionis Pharmaceuticals | IONS | Downgrade | Underperform (Buy) |
31.80 (42.04) |
32.2% | Details | |
| 2/1/2022 | Mirati Therapeutics | MRTX | Upgrade | Neutral (Underperform) |
119.30 (58.70) |
-50.8% | Details | |
| 12/8/2021 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 12/2/2021 | BeyondSpring Inc. | BYSI | Downgrade | Underperform (Buy) |
12.77 (2.33) |
-81.75% | Details | |
| 11/16/2021 | Alkermes | ALKS | Maintain | Underperform (N/A) |
|
Details | ||
| 11/16/2021 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/12/2021 | Organon & Co. | OGN | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2021 | FibroGen | FGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/10/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2021 | Cara Therapeutics | CARA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/9/2021 | Alkermes | ALKS | Maintain | Underperform (N/A) |
|
Details | ||
| 11/9/2021 | Viatris | VTRS | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2021 | Galapagos NV | GLPG | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2021 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2021 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2021 | DICE Therapeutics | DICE | New Coverage | Buy (N/A) |
26.49 (47.55) |
79.5% | Details | |
| 9/17/2021 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 9/13/2021 | BeyondSpring Inc. | BYSI | Maintain | Buy (N/A) |
|
Details | ||
| 9/2/2021 | Alkermes | ALKS | Downgrade | Underperform (Neutral) |
31.25 (22.72) |
-27.3% | Details | |
| 9/1/2021 | Organon & Co. | OGN | New Coverage | Buy (N/A) |
33.89 (18.60) |
-45.12% | Details | |
| 8/4/2021 | Bausch Health Companies | BHC | Maintain | Underperform (N/A) |
|
Details | ||
| 8/4/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 7/16/2021 | FibroGen | FGEN | Downgrade | Neutral (Buy) |
24.84 (0.96) |
-96.14% | Details | |
| 6/28/2021 | FibroGen | FGEN | Maintain | Buy (N/A) |
|
Details | ||
| 6/22/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 6/22/2021 | Tarsus Pharmaceuticals | TARS | Maintain | Buy (N/A) |
|
Details | ||
| 5/25/2021 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2021 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2021 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/4/2021 | Coherus Biosciences | CHRS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 2/9/2021 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 1/11/2021 | BeyondSpring Inc. | BYSI | New Coverage | Buy (N/A) |
12.62 (2.33) |
-81.54% | Details | |
| 12/11/2020 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 12/1/2020 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2020 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 10/26/2020 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/21/2020 | Cara Therapeutics | CARA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/12/2020 | Arena Pharma | ARNA | Maintain | Buy (N/A) |
|
Details | ||
| 8/21/2020 | Galapagos NV | GLPG | Maintain | Underperform (N/A) |
|
Details | ||
| 8/6/2020 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 7/22/2020 | Arena Pharma | ARNA | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2020 | Vaxcyte | PCVX | New Coverage | Buy (N/A) |
29.38 (59.45) |
102.35% | Details | |
| 6/19/2020 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 5/26/2020 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2020 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2020 | Cara Therapeutics | CARA | Maintain | Neutral (N/A) |
|
Details | ||
| 3/26/2020 | Galapagos NV | GLPG | Maintain | Underperform (N/A) |
|
Details | ||
| 2/25/2020 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2020 | Alkermes | ALKS | Downgrade | Neutral (Buy) |
17.65 (23.91) |
35.47% | Details | |
| 2/13/2020 | Teva Pharma | TEVA | Maintain | Underperform (N/A) |
|
Details | ||
| 1/31/2020 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2020 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2020 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 12/31/2019 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2019 | Exelixis | EXEL | New Coverage | Buy (N/A) |
15.34 (23.47) |
53% | Details | |
| 11/13/2019 | Arena Pharma | ARNA | New Coverage | Neutral (N/A) |
46.17 (41.50) |
-10.11% | Details | |
| 10/17/2019 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
109.70 (720.64) |
556.92% | Details | |
| 10/10/2019 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 9/12/2019 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2019 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 9/5/2019 | Mallinckrodt plc | MNK | Maintain | Underperform (N/A) |
|
Details | ||
| 9/3/2019 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/20/2019 | Nabriva Therapeutics AG | NBRV | Maintain | Buy (N/A) |
|
Details | ||
| 7/30/2019 | Pfizer | PFE | Downgrade | Neutral (Buy) |
41.45 (36.50) |
-11.94% | Details | |
| 6/25/2019 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 6/21/2019 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 5/30/2019 | Teva Pharma | TEVA | Downgrade | Underperform (Neutral) |
9.70 (12.95) |
33.51% | Details | |
| 5/1/2019 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 4/1/2019 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 3/27/2019 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2019 | Banco de Chile | BCH | New Coverage | Underperform (N/A) |
31.19 (22.26) |
-28.63% | Details | |
| 3/7/2019 | Allergen | AGN | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2019 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2019 | Allergen | AGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2019 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2019 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/25/2019 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/15/2019 | Cara Therapeutics | CARA | New Coverage | Neutral (N/A) |
15.83 (0.66) |
-95.83% | Details | |
| 1/3/2019 | Mylan | MYL | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2019 | Allergen | AGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2019 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/3/2019 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2019 | Abbvie | ABBV | Downgrade | Neutral (Buy) |
89.23 (166.06) |
86.1% | Details | |
| 1/3/2019 | Teva Pharma | TEVA | Upgrade | Buy (Underperform) |
15.85 (9.70) |
-38.8% | Details | |
| 12/12/2018 | Foamix Pharmaceuticals | FOMX | New Coverage | Buy (N/A) |
4.00 (2.99) |
-25.25% | Details | |
| 11/30/2018 | Alkermes | ALKS | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2018 | Mylan | MYL | Upgrade | Buy (Neutral) |
31.37 (15.86) |
-49.44% | Details | |
| 10/16/2018 | Spero Therapeutics | SPRO | Downgrade | Underperform (Neutral) |
9.60 (1.43) |
-85.1% | Details | |
| 10/4/2018 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 8/27/2018 | Nabriva Therapeutics AG | NBRV | Maintain | Buy (Buy) |
|
Details | ||
| 8/27/2018 | Paratek Pharmaceuticals | PRTK | New Coverage | Neutral (N/A) |
10.35 (2.23) |
-78.45% | Details |
